"""
Question: 1101 

Evidence: In this study, we analyzed the mutation patterns leading to virologic failure before and after starting integrase strand transfer inhibitor-based regimen as first-line or salvage therapy. Between 2016 and 2019, blood samples were received from 258 patients with HIV-1 infection.

Rationale: The paper describes a specific cohort, time frame, and analyses undertaken by the authors, indicating original data collection and analysis rather than a review of previously published data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Plasma HIV-1 RNA concentrations, and pol gene sequences were determined at baseline, and 16–48 weeks of treatment with integrase strand transfer inhibitor-based regimen. The ABI 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA) was used to determine the nucleotide sequences of 5' and 3' DNA strands as described previously.

Rationale: The methods explicitly state that pol gene sequences were generated from patient samples, confirming that HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: In this study, we analyzed the mutation patterns leading to virologic failure before and after starting integrase strand transfer inhibitor-based regimen as first-line or salvage therapy. Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks.

Rationale: The study is an observational clinical cohort with patient follow-up, not an in vitro experiment; no passages of virus in cell culture are described.

Answer: No
"""

"""
Question: 1104 

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm. Major and accessory mutations conferring high level resistance to RAL and to the NRTIs, 3TC and FTC, were detected in HIV-1 sequence of patient "2".

Rationale: The paper reports genotypic resistance mutations; there is no description of phenotypic susceptibility assays or in vitro drug susceptibility measurements.

Answer: No
"""

"""
Question: 2101 

Evidence: Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene, as described previously. The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper describes sequencing and analysis but does not provide any GenBank accession numbers; no such identifiers appear in the text.

Answer: No
"""

"""
Question: 2102 

Evidence: Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene, as described previously. The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: There are no GenBank accession numbers reported for any sequences, including clinical isolates; the paper contains no accession identifiers.

Answer: No
"""

"""
Question: 2103 

Evidence: Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene, as described previously. The ABI 3500 Genetic Analyzer was used to determine the nucleotide sequences.

Rationale: The manuscript does not list any GenBank accession numbers; therefore none can be provided.

Answer: NA
"""

"""
Question: 2202 

Evidence: Table 2. Mutations associated with resistance to reverse transcriptase or integrase inhibitors in patients with virologic failure. Patients "4" through "7" who had no previous exposure to ART, failed RAL-based regimen offered as first-line treatment.

Rationale: Table 2 provides per-patient lists of NRTI, NNRTI, and InSTI mutations, i.e., mutation lists for individual sequenced isolates.

Answer: Yes
"""

"""
Question: 2301 

Evidence: Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks. Between 2016 and 2019, blood samples were received from 258 patients with HIV-1 infection.

Rationale: The infection and sequencing targets are explicitly HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: One patient was infected with HIV-1 subtype C, and the rest with subtype CRF01_AE. All patients with virologic failure but one were infected with CRF01_AE virus subtype.

Rationale: The paper specifies the subtypes for the sequenced viruses among the seven patients with virologic failure.

Answer: CRF01_AE and C
"""

"""
Question: 2303 

Evidence: Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene. Plasma HIV-1 RNA concentrations, and pol gene sequences were determined at baseline, and 16–48 weeks of treatment.

Rationale: The sequenced regions are explicitly listed: protease, reverse transcriptase, and integrase within pol.

Answer: Protease, reverse transcriptase, integrase (pol)
"""

"""
Question: 2304 

Evidence: Plasma HIV-1 RNA concentrations, and pol gene sequences were determined at baseline, and 16–48 weeks of treatment with integrase strand transfer inhibitor-based regimen. Table 2 shows the detected mutations in reverse transcriptase and integrase.

Rationale: The study reports results from sequencing of the pol gene regions, including identified mutations.

Answer: Yes
"""

"""
Question: 2401 

Evidence: Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks. There were all recruited from Infectious Disease Hospital, Ministry of Health, Kuwait.

Rationale: The recruitment site and patient nationality indicate the geographic origin of the sequences.

Answer: Kuwait
"""

"""
Question: 2402 

Evidence: The study period was from January 2016 to December 2019. Between 2016 and 2019, blood samples were received from 258 patients with HIV-1 infection.

Rationale: These sentences specify the years during which samples were collected and analyzed.

Answer: 2016–2019
"""

"""
Question: 2502 

Evidence: The ABI 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA) was used to determine the nucleotide sequences of 5' and 3' DNA strands as described previously. This resulted in detection missing due to the low sensitivity of Sanger bulk sequencing that is known to detect only variants with prevalence of more than 20%.

Rationale: The use of an ABI 3500 and the explicit mention of Sanger bulk sequencing confirm that Sanger sequencing was used.

Answer: Yes
"""

"""
Question: 2503 

Evidence: This resulted in detection missing due to the low sensitivity of Sanger bulk sequencing that is known to detect only variants with prevalence of more than 20%. Another important factor is the low adherence to medications, and the prolonged interval between the time of antiretroviral drug discontinuation and genotypic testing.

Rationale: The paper explicitly refers to Sanger sequencing and does not describe any next-generation sequencing.

Answer: No
"""

"""
Question: 2504 

Evidence: The ABI 3500 Genetic Analyzer was used to determine the nucleotide sequences of 5' and 3' DNA strands as described previously. Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region.

Rationale: The methods describe direct PCR amplification and Sanger sequencing; there is no mention of cloning PCR products prior to sequencing.

Answer: NA
"""

"""
Question: 2505 

Evidence: This resulted in detection missing due to the low sensitivity of Sanger bulk sequencing that is known to detect only variants with prevalence of more than 20%. The ABI 3500 Genetic Analyzer was used to determine the nucleotide sequences.

Rationale: The description of bulk Sanger sequencing indicates that single-genome sequencing was not performed.

Answer: No
"""

"""
Question: 2506 

Evidence: Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene. The ABI 3500 Genetic Analyzer was used to determine the nucleotide sequences.

Rationale: The methodology describes direct sequencing of PCR amplicons without molecular cloning; no cloning steps are mentioned.

Answer: No
"""

"""
Question: 2601 

Evidence: HIV-1 RNA concentrations in the plasma samples of patients were measured within 16--48 weeks of treatment. The MagNa Pure LC 2.0 system was used to isolate total RNA from plasma samples.

Rationale: Sequencing was performed on RNA extracted from plasma samples, indicating plasma HIV sequencing.

Answer: Yes
"""

"""
Question: 2602 

Evidence: The MagNa Pure LC 2.0 system was used to isolate total RNA from plasma samples. Two nested RT-PCRs were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene.

Rationale: Only plasma RNA is mentioned; there is no mention of PBMC-derived DNA or RNA sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: Plasma HIV-1 RNA concentrations, and pol gene sequences were determined at baseline, and 16–48 weeks of treatment with integrase strand transfer inhibitor-based regimen. Only patients who did not achieve viral suppression at 48 weeks of integrase strand transfer inhibitor-based treatment were eligible for the current study.

Rationale: Although sequencing was performed for the seven failing patients, the exact number of sequenced plasma samples (timepoints per person) is not specified.

Answer: NA
"""

"""
Question: 2604 

Evidence: The MagNa Pure LC 2.0 system was used to isolate total RNA from plasma samples. There is no mention of PBMC processing or sequencing.

Rationale: The study did not perform PBMC virus sequencing; hence the count is zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: Virologic failure is defined as viral load above 200 copies/mL on at least two consecutive measurements. Virologic failure was observed in seven patients on raltegravir-based regimen.

Rationale: Sequencing was conducted in patients with virologic failure and detectable viremia, indicating active HIV replication.

Answer: Yes
"""

"""
Question: 2606 

Evidence: The MagNa Pure LC 2.0 system was used to isolate total RNA from plasma samples. Two nested RT-PCRs were performed to amplify the protease/reverse transcriptase region, and the integrase region.

Rationale: Sequencing was performed on plasma RNA, not on proviral DNA; therefore sequences were not from the proviral DNA reservoir.

Answer: No
"""

"""
Question: 2701 

Evidence: Their median age was 40 years (range, 4--45 years). Table 1 shows patients aged 7 and 4 years.

Rationale: The age range and table demonstrate inclusion of children.

Answer: Yes
"""

"""
Question: 2702 

Evidence: Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks. There were all recruited from Infectious Disease Hospital, Ministry of Health, Kuwait.

Rationale: The study is an observational cohort from a hospital setting; there is no mention of a clinical trial, but this cannot be definitively confirmed as not a trial from the text alone.

Answer: NA
"""

"""
Question: 2703 

Evidence: Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks. There were all recruited from Infectious Disease Hospital, Ministry of Health, Kuwait.

Rationale: The paper does not state that participants were in a clinical trial; thus it cannot be concluded that all were trial participants.

Answer: NA
"""

"""
Question: 3101 

Evidence: Among patients treated with InSTI-based regimen, virologic failure was observed in a total of seven patients on RAL-based regimen. Plasma HIV-1 RNA concentrations, and pol gene sequences were determined at baseline, and 16–48 weeks of treatment.

Rationale: The study focuses on seven failing patients and sequenced their pol genes; therefore seven individuals had samples obtained for sequencing.

Answer: 7
"""

"""
Question: 3102 

Evidence: Plasma HIV-1 RNA concentrations, and pol gene sequences were determined at baseline, and 16–48 weeks of treatment with integrase strand transfer inhibitor-based regimen. Only patients who did not achieve viral suppression at 48 weeks of integrase strand transfer inhibitor-based treatment were eligible for the current study.

Rationale: All seven included individuals (those with virologic failure) had sequencing performed per the methods.

Answer: Yes
"""

"""
Question: 4101 

Evidence: Patients "4" through "7" who had no previous exposure to ART, failed RAL-based regimen offered as first-line treatment. Baseline HIV-1 genotyping results showed the presence of integrase and reverse transcriptase gene polymorphism in only two patients, "4" and "6".

Rationale: The paper explicitly identifies ART-naive individuals whose viruses were sequenced.

Answer: Yes
"""

"""
Question: 4102 

Evidence: Patients "1" through "3" were offered RAL-based regimen as second-line therapy, following a virologic failure with NNRTI-based regimen. HIV-1 reverse transcriptase gene from patient "1" had developed mutations associated with high level resistance to all available NNRTIs.

Rationale: These sentences show sequencing from ART-experienced individuals.

Answer: Yes
"""

"""
Question: 4103 

Evidence: Patients "1" through "3" were offered RAL-based regimen as second-line therapy, following a virologic failure with NNRTI-based regimen. Patients "4" through "7" who had no previous exposure to ART, failed RAL-based regimen offered as first-line treatment.

Rationale: Both ART-experienced and ART-naive individuals' viruses were sequenced.

Answer: Yes
"""

"""
Question: 4104 

Evidence: Patients "4" through "7" who had no previous exposure to ART, failed RAL-based regimen offered as first-line treatment. One patient was infected with HIV-1 subtype C, and the rest with subtype CRF01_AE.

Rationale: Four individuals (patients 4–7) were ART-naive.

Answer: 4
"""

"""
Question: 4105 

Evidence: Patients "1" through "3" were offered RAL-based regimen as second-line therapy, following a virologic failure with NNRTI-based regimen. Patients "4" through "7" who had no previous exposure to ART, failed RAL-based regimen offered as first-line treatment.

Rationale: The paper provides prior ART exposure status for each patient group, covering all seven individuals.

Answer: Yes
"""

"""
Question: 4201 

Evidence: In our previous studies, we reported the detection of major mutations conferring resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors (NNRTIs) in 12.5% of 64 ART-naive patients, and about 30% of 64 treatment-experienced patients. Given the scarce information on HIV-1 drug resistance in real clinical settings, especially in the Arabian Gulf region, we aimed in this report to characterize the patterns of mutations detected among patients who did not achieve viral suppression.

Rationale: The current paper does not present prevalence of transmitted resistance; it focuses on mutation patterns in failing patients.

Answer: No
"""

"""
Question: 4202 

Evidence: Baseline HIV-1 genotyping results showed the presence of integrase and reverse transcriptase gene polymorphism in only two patients, "4" and "6". We aimed in this report to characterize the patterns of mutations detected among patients who did not achieve viral suppression following 48 weeks of treatment with InSTI-based regimen.

Rationale: The study does not quantify the prevalence of pretreatment resistance in a defined baseline cohort; it focuses on failing cases.

Answer: No
"""

"""
Question: 4301 

Evidence: Raltegravir based-regimen was offered as first-line therapy for four patients, and as salvage therapy for three patients. The InSTI-based regimen generally consists of one InSTI plus two nucleoside reverse transcriptase inhibitors (NRTIs).

Rationale: All individuals received an integrase inhibitor (RAL) with NRTIs; some had prior NNRTI-based therapy.

Answer: Integrase inhibitors (INSTIs), NRTIs, and previously NNRTIs
"""

"""
Question: 4302 

Evidence: Among patients treated with InSTI-based regimen, virologic failure was observed in a total of seven patients on RAL-based regimen. Raltegravir based-regimen was offered as first-line therapy for four patients, and as salvage therapy for three patients.

Rationale: All seven individuals received an integrase inhibitor (raltegravir).

Answer: Yes
"""

"""
Question: 4303 

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm. Patients "1" through "3" were offered RAL-based regimen as second-line therapy, following a virologic failure with NNRTI-based regimen.

Rationale: The paper does not report PI-containing regimens being used by these individuals; it focuses on INSTI-based regimens and prior NNRTI regimens.

Answer: No
"""

"""
Question: 4304 

Evidence: RAL + TDF/FTC, RAL + ABC/3TC, and RAL + AZT/3TC were used (Table 1). Patient receiving 100 mg raltegravir twice daily and patient receiving 400 mg raltegravir twice daily are both reported.

Rationale: Different NRTI backbones and different RAL dosing regimens were used; therefore regimens were not identical.

Answer: No
"""

"""
Question: 4305 

Evidence: Patients "1" through "3" were on NNRTI-based regimen before starting RAL-based regimen as salvage therapy. Patients "4" through "7" who had no previous exposure to ART, failed RAL-based regimen offered as first-line treatment.

Rationale: None had prior exposure to integrase inhibitors before starting RAL-based regimens.

Answer: Yes
"""

"""
Question: 4403 

Evidence: Patients "1" through "3" were offered RAL-based regimen as second-line therapy, following a virologic failure with NNRTI-based regimen. Patients "4" through "7" were offered RAL-based regimen as first-line therapy.

Rationale: Three individuals had more than one ART regimen (prior NNRTI-based plus RAL-based), whereas four had only one.

Answer: 3
"""

"""
Question: 4404 

Evidence: Patients "1" through "3" were offered RAL-based regimen as second-line therapy, following a virologic failure with NNRTI-based regimen. The paper does not describe additional prior or subsequent regimens.

Rationale: There is insufficient information to determine if anyone had more than two regimens.

Answer: NA
"""

"""
Question: 4405 

Evidence: Patients "1" through "3" were on NNRTI-based regimen before starting RAL-based regimen as salvage therapy. Patients "4" through "7" were offered RAL-based regimen as first-line treatment.

Rationale: Some participants had two regimens while others had one, indicating not all had the same number of regimens.

Answer: No
"""

"""
Question: 4406 

Evidence: Patients "1" through "3" were offered RAL-based regimen as second-line therapy, following a virologic failure with NNRTI-based regimen. Patients "4" through "7" were offered RAL-based regimen as first-line treatment.

Rationale: Because three had previous regimens, not all received only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: Virologic failure was observed in seven patients on raltegravir-based regimen, while viral suppression was achieved in all patients on EVG-based regimen (Stribild or Genvoya), or DTG-based regimen (Tivicay + Descovy or Truvada or Epzicom). Table 1 lists only raltegravir-containing regimens for the seven patients with virologic failure.

Rationale: The paper does not provide the count of individuals on dolutegravir overall; among the seven analyzed patients, none received dolutegravir.

Answer: NA
"""

"""
Question: 4502 

Evidence: Table 1 shows the InSTI-based regimens as RAL + TDF/FTC, RAL + ABC/3TC, or RAL + AZT/3TC. There is no mention of darunavir-containing regimens.

Rationale: The study cohort described did not include PI-based regimens with darunavir.

Answer: 0
"""

"""
Question: 5101 

Evidence: M184V mutation associated with high level resistance to lamivudine (3TC) and FTC was detected in six out of seven patients (Table 2). HIV-1 reverse transcriptase gene from patient "1" had developed mutations associated with high level resistance to all available NNRTIs.

Rationale: Six had M184V and the remaining patient had NNRTI resistance mutations; thus all seven had at least one drug resistance mutation.

Answer: 7
"""

"""
Question: 5102 

Evidence: Primary mutations (Y143C, N155H, T66I, G118R, E138K) conferring high level resistance to raltegravir were detected in only three patients. Pre-existing polymorphic integrase mutation (T97A) was detected in two patients.

Rationale: Three patients had primary INSTI-resistance mutations and two had T97A (an INSTI-associated accessory mutation), totaling five individuals with INSTI-resistance mutations.

Answer: 5
"""

"""
Question: 5103 

Evidence: Table 2 shows for patient "2": NRTI mutations K70E, M184V. M184V mutation associated with high level resistance to lamivudine (3TC) and FTC was detected in six out of seven patients.

Rationale: K70E is associated with reduced susceptibility to TDF; it appears only in patient 2.

Answer: 1
"""

"""
Question: 5104 

Evidence: Primary mutations (Y143C, N155H, T66I, G118R, E138K) conferring high level resistance to raltegravir were detected in only three patients. Table 2 lists additional integrase-associated mutations T97A, E157Q, and S230R.

Rationale: The INSTI-resistance mutations reported include Y143C, N155H, T66I, G118R, E138K (primary) and T97A, E157Q, S230R (accessory/polymorphic).

Answer: Y143C, N155H, T66I, G118R, E138K, T97A, E157Q, S230R
"""

"""
Question: 6101 

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm. This study analyzed mutations before and after starting InSTI-based regimen.

Rationale: The paper reports only genotypic analysis and does not describe any phenotypic susceptibility testing method.

Answer: NA
"""

"""
Question: 6102 

Evidence: The identification of mutations was done using a genotypic resistance interpretation algorithm. There is no mention of IC50 or IC90 measurements.

Rationale: The paper contains no phenotypic IC values.

Answer: No
"""

"""
Question: 6103 

Evidence: The study reports genotypic resistance mutations and clinical outcomes. There is no mention of fold change in IC50.

Rationale: No phenotypic fold-change data are provided.

Answer: No
"""

"""
Question: 6104 

Evidence: The identification of mutations was done using the Stanford University genotypic resistance interpretation algorithm. No phenotypic assay methods are described.

Rationale: The study did not perform phenotypic susceptibility assays.

Answer: NA
"""

"""
Question: 6105 

Evidence: The study focuses on virologic failure and resistance mutations. There is no mention of replication capacity measurements.

Rationale: Replication capacity data are absent.

Answer: No
"""

"""
Question: 6106 

Evidence: The paper reports only genotypic mutations and clinical regimens. No phenotypic testing or drugs tested in such assays are described.

Rationale: Since no phenotypic assays were performed, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: Two nested RT-PCRs were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene. The sequences and mutations reported are derived from patient samples and clinical follow-up.

Rationale: There is no mention of constructing site-directed mutant viruses; all mutations arose in vivo.

Answer: No
"""

"""
Question: 7102 

Evidence: Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks. The study analyzes mutations arising during clinical treatment without in vitro passage.

Rationale: No in vitro passage experiments are described.

Answer: No
"""